ライフサイエンスコーパス: lung transplantation

1 mize lung preservation leading to successful lung transplantation.

2 approach leading to long-term success after lung transplantation.

3 The primary outcome was death or lung transplantation.

4 jor limiting factor of long-term survival in lung transplantation.

5 ppropriate management and early referral for lung transplantation.

6 and waitlist deaths were seen in kidney and lung transplantation.

7 ng used as a reason to exclude patients from lung transplantation.

8 patients (93 of 256) died, and one underwent lung transplantation.

9 ge is thought to be important for successful lung transplantation.

10 olar lavages obtained from 116 patients post lung transplantation.

11 cognitive dysfunction (POCD) is common after lung transplantation.

12 AT1R and ETAR antibodies on graft outcome in lung transplantation.

13 major cause of morbidity and mortality after lung transplantation.

14 ory failure provided they are candidates for lung transplantation.

15 and clinical effects of CMVIG after heart or lung transplantation.

16 r rate of respiratory failure while awaiting lung transplantation.

17 O) is being increasingly used as a bridge to lung transplantation.

18 LAD) is a major cause of allograft loss post-lung transplantation.

19 olar lavages obtained from 112 patients post-lung transplantation.

20 rimary outcome was the composite of death or lung transplantation.

21 a median of 86 days (range, 44-185 d) after lung transplantation.

22 seudomonas associated allograft injury after lung transplantation.

23 major limitation of long-term survival after lung transplantation.

24 d the risk of both CLAD and graft loss after lung transplantation.

25 vative strategy of organ preservation before lung transplantation.

26 ms involved in the development of CLAD after lung transplantation.

27 y to prevent primary graft dysfunction after lung transplantation.

28 model reproducing the procedural sequence of lung transplantation.

29 B-related disease with a particular focus on lung transplantation.

30 ejection is a major cause of morbidity after lung transplantation.

31 rognosis in patients that do not qualify for lung transplantation.

32 ng treatment strategy for infants undergoing lung transplantation.

33 is (IPA) is a significant complication after lung transplantation.

34 transplantation but has not been examined in lung transplantation.

35 primary graft failure or survival following lung transplantation.

36 sence of these organisms should not preclude lung transplantation.

37 siology of AR and for biomarker discovery in lung transplantation.

38 von Willebrand deficiency corrected through lung transplantation.

39 ous entity limiting long-term survival after lung transplantation.

40 al in a preclinical model of orthotopic left lung transplantation.

41 dence of acute rejection and infection after lung transplantation.

42 ing hazard associated with single- vs double-lung transplantation.

43 en referred to our center for evaluation for lung transplantation.

44 A total of 93 CF patients underwent lung transplantation.

45 ized long-term postoperative complication of lung transplantation.

46 promising approach to prevent IRI following lung transplantation.

47 s investigated in an orthotopic rat model of lung transplantation.

48 ection represent major caveats to successful lung transplantation.

49 diagnosis of antibody-mediated rejection in lung transplantation.

50 itical to improving long-term survival after lung transplantation.

51 recent changes and advancements in heart and lung transplantation.

52 for clinical trials on immunosuppressants in lung transplantation.

53 tion to prevent and/or treat ACR in clinical lung transplantation.

54 ntaneously breathing patients as a bridge to lung transplantation.

55 ed their impact on outcomes before and after lung transplantation.

56 he isolation of Pseudomonas aeruginosa after lung transplantation.

57 n, have somewhat arbitrarily been applied to lung transplantation.

58 rent recommendations regarding pregnancy and lung transplantation.

59 these diagnostic pillars are less robust in lung transplantation.

60 ear whether a VEGF blockade is beneficial in lung transplantation.

61 the use of extended-criteria donor organs in lung transplantation.

62 ociated with constrictive pericarditis after lung transplantation.

63 which requires life-saving measures, such as lung transplantation.

64 before and at 3- to 6-month intervals after lung transplantation.

65 vasculature and donor-host connections after lung transplantation.

66 ecurrent pleural effusions within 2 years of lung transplantation.

67 of primary graft dysfunction (PGD) following lung transplantation.

68 improving patient outcomes before and after lung transplantation.

69 ojects to address these gaps in the field of lung transplantation.

70 simultaneous LLT was comparable to isolated lung transplantation.

71 dococcus equi infection in an allograft post-lung transplantation.

72 on analysis in the context of unmet needs in lung transplantation.

73 h a three-phage cocktail following bilateral lung transplantation.

74 l use of F-FDG PET/CT during follow-up after lung transplantation.

75 ects of antibody-mediated rejection (AMR) in lung transplantation.

76 y was most outspoken in the first year after lung transplantation.

77 6516 kidney, 2606 liver, 929 heart, and 705 lung transplantations.

78 and limited availability of donor organs for lung transplantation(1).

79 nts were included (26 patients had undergone lung transplantation, 13 liver, 6 kidney, and 2 heart tr

80 She had previously undergone bilateral lung transplantation 18 years earlier, as well as two ki

81 nced lung disease who subsequently underwent lung transplantation (2004-2012).

82 (ISHLT [International Society for Heart and Lung Transplantation] 2013 grades), immunostaining, and

83 Of the 10,225 patients who underwent lung transplantation, 3127 (30.6%) had allografts expose

84 , 2.21; 95% CI, 1.53-3.17, P<0.001; HR after lung transplantation, 5.83; 95% CI, 3.12-10.9, P<0.001.

85 The patient had undergone left lung transplantation 8 years prior for pulmonary fibrosi

86 tal of 14 of 15 patients who did not undergo lung transplantation (93.3%) died after 40.3 +/- 27.8 da

87 D+/R- heart transplant patients, whereas in lung transplantation, addition of CMVIG in recipients of

88 were independently associated with death or lung transplantation, adjusted for age, sex, and type of

89 hnique have contributed to improved outcomes.Lung transplantation advancements include the increasing

90 els were studied: hilar clamp and orthotopic lung transplantation after prolonged cold ischemia (OLT-

91 th idiopathic pulmonary fibrosis by risk for lung transplantation allocation who have the same clinic

92 surgery and Psychiatry, Journal of Heart and Lung Transplantation, American Journal of Transplantatio

93 .75; p=0.0011) for the composite of death or lung transplantation and 1.27 (1.00-1.60; p=0.046) for a

94 n=7) from patients with PAH undergoing heart/lung transplantation and compared with tissue obtained f

95 s at the site of anastomosis by day 14 after lung transplantation and formed physical connections wit

96 n one of the most common complications after lung transplantation and have been linked to allograft d

97 t stature is associated with a lower rate of lung transplantation and higher rates of death and respi

98 rus (CARV) infections occur frequently after lung transplantation and may adversely impact outcomes.

99 These Abs can also develop de novo after lung transplantation and mediate allograft rejection.

100 ograft fibrogenesis in the context of single-lung transplantation and represents a major step forward

101 ain cause of primary graft dysfunction after lung transplantation and results in increased morbidity

102 dications are expanding to being a bridge to lung transplantation and the management of patients with

103 p of the International Society for Heart and Lung Transplantation and The Transplantation Society.

104 Pulmonary masses occasionally occur after lung transplantation and vary in etiology, which include

105 d in lung tissues of IPF subjects undergoing lung transplantation, and CCN1 protein was predominantly

106 ajor barrier to long-term survival following lung transplantation, and new mechanistic biomarkers are

107 s from older donors are increasingly used in lung transplantation, and studies have demonstrated that

108 continues to be a vexing problem in clinical lung transplantation, and the role played by passenger l

109 ce in rejection following kidney, heart, and lung transplantation, and their implication in serum rea

110 fective strategies to prevent IFIs following lung transplantation are not known.

111 al follow up and vaccination responses after lung transplantation are scarce.

112 ter were at increased risk of mortality with lung transplantation as a censoring event, after adjusti

113 acic cavity several days following bilateral lung transplantation, as an unusual complication.

114 For kidney, liver, and lung transplantation, assessment windows of at least 18

115 .05) were significant predictors of death or lung transplantation at 10-year follow-up.

116 clinical data on all patients who underwent lung transplantation at a tertiary care academic hospita

117 ber 2018, 1234 patients underwent orthotopic lung transplantation at Duke University Hospital.

118 were independently associated with death or lung transplantation at first follow-up RHC after initia

119 Seventy-three had died or underwent lung transplantation at the time of the study with a med

120 ctor (vWF) was significantly increased after lung transplantation because lung endothelial cells stro

121 LTRs) may be at greater risk of IA following lung transplantation because of the presence of Aspergil

122 hort study including all patients listed for lung transplantation between January 2008 and August 201

123 l adults (age >=18) who underwent first-time lung transplantation between March 2018 (when united net

124 Bilateral lung transplantation (BLTx) is an established treatment

125 This multicenter study reviews all bilateral lung transplantations (BLTx) from donors 55 years or old

126 let mismatch is well documented in renal and lung transplantation but there is no clear evidence in l

127 cause of early morbidity and mortality after lung transplantation, but the immunologic mechanisms are

128 -11.3) and methotrexate (3.3, 1.0-10.2); for lung transplantation, carmustine (12.3, 3.1-48.9) and me

129 Bacterial infections after lung transplantation cause airway epithelial injury and

130 The primary outcome was the time until lung transplantation censored at 1 year.

131 motherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tum

132 In lung transplantation, CMVIG should again only be used wi

133 the null/null infants had died or undergone lung transplantation compared with 62% of the null/other

134 Lung transplantation confers large HRQL benefits, which

135 of cystic fibrosis (CF) patients undergoing lung transplantation continues to grow, as does the prev

136 tory tests at 5, 11, 14, and 22 months after lung transplantation demonstrated sustained normalizatio

137 t requirements for tolerance induction after lung transplantation differ from other organs.

138 In lung transplantation, diverse clinical events may impact

139 study included adult patients who underwent lung transplantation during 2005-2008.

140 GD remains a threat to the 2 primary aims of lung transplantation, extending survival and improving H

141 Patients awaiting lung transplantation face high wait-list mortality, as i

142 Immunosuppression therapy after lung transplantation fails to prevent bronchiolitis obli

143 Immunosuppression therapy following lung transplantation fails to prevent bronchiolitis obli

144 d to our institution and underwent bilateral lung transplantation for cystic fibrosis.

145 Lung transplantation for infants and children is an acce

146 ut ECMO (BLTx ventilation) or combined heart-lung transplantation for severe PH.

147 -type natriuretic peptide, hemodynamics) and lung-transplantation-free survival.

148 ed for adult candidates for LLT and isolated lung transplantation from 2006 to 2016.

149 ectively followed 130 subjects who underwent lung transplantation from 2012 to 2016.

150 eight were finally found to be suitable for lung transplantation from an ECMO bridge.

151 igs (n = 12) were randomized to undergo left lung transplantation from male donors either using the g

152 was queried for adult patients who underwent lung transplantation from May 1, 2005, through December

153 base, all adult patients undergoing isolated lung transplantation from May 2005 through September 201

154 with ILD referred or on the waiting list for lung transplantation from May 2013 to December 2017 unde

155 R (pAMR) International Society for Heart and Lung Transplantation grade (P<0.001) and association wit

156 fined as International Society for Heart and Lung Transplantation grade 2R or higher cellular rejecti

157 tion (>/= International Society of Heart and Lung Transplantation grade 2R); however, the frequency o

158 tion and International Society for Heart and Lung Transplantation grade and the performance metrics o

159 Despite International Society for Heart and Lung Transplantation guidelines, a significant proportio

160 ing 2010 International Society for Heart and Lung Transplantation guidelines.

161 Central airway stenosis (CAS) after lung transplantation has been attributed in part to chro

162 The International Society for Heart and Lung Transplantation has guidelines regarding reproducti

163 eases, but the exact role of eosinophilia in lung transplantation has not been thoroughly investigate

164 Since the 1960s, heart and lung transplantation has remained the optimal therapy fo

165 Recent insights from animal models of lung transplantation have established that Tregs play a

166 Outcomes of single- and double-lung transplantation have not been rigorously assessed s

167 pecific HLA antibody (DSA) development after lung transplantation have not been systematically evalua

168 atients with chronic lung disease undergoing lung transplantation have pre-existing Abs against lung-

169 lation (MV) can be used as a bridge to heart-lung transplantation (HLT).

170 Heart-lung transplantation (HLTx) is an effective treatment fo

171 d with a higher composite endpoint of death, lung transplantation, hospitalization, or FVC decline fo

172 mortality in patients with ILD referred for lung transplantation in an Australian cohort.

173 formation to established predictors of death/lung transplantation in CF.

174 iated with better graft survival than single-lung transplantation in patients with IPF.

175 l outcomes for patients after combined heart-lung transplantation in the current era.

176 Despite its complexity, lung transplantation in the cystic fibrosis population i

177 utive adult patients (>=18 years) undergoing lung transplantation in the Hospital Universitari Vall d

178 s not associated with 1-year mortality after lung transplantation in the LAS era, perhaps because of

179 year mortality in 9,073 adults who underwent lung transplantation in the United States between May 20

180 ctive pulmonary disease (COPD) who underwent lung transplantation in the United States between May 4,

181 Lung transplantation in the United States continues to b

182 Patients with CF who underwent lung or heart-lung transplantation in the United States or United King

183 ansplant-free survival (ie, time to death or lung transplantation) in the Dallas cohort.

184 After lung transplantation, increased left ventricular (LV) fi

185 43 in kidney, 17 in heart, 12 in liver, 1 in lung transplantation) investigated 95 correlates and 24

186 Lung transplantation is a crucial component in the treat

187 Heart lung transplantation is a viable treatment option for pa

188 The survival rate following lung transplantation is among the lowest of all solid-or

189 reatment, prognosis remains poor, and double-lung transplantation is an option for eligible patients.

190 ent of donor-specific antibodies (DSA) after lung transplantation is associated with antibody mediate

191 ischemia (>/=6 hours) on outcomes following lung transplantation is controversial.

192 issues and organs, tolerance induction after lung transplantation is critically dependent on central

193 timulation blockade-mediated tolerance after lung transplantation is dependent on programmed cell dea

194 Lymphatic drainage after lung transplantation is established by active sprouting

195 evidence for mTOR inhibitor use in heart and lung transplantation is examined in this review.

196 Lung transplantation is limited by a scarcity of suitabl

197 Survival after lung transplantation is mainly limited by the developmen

198 nhibitors in de novo immunosuppression after lung transplantation is not well defined.

199 respiratory failure within 2-4 years unless lung transplantation is performed.

200 Heart-lung transplantation or bilateral lung transplantation is the final pathway for a minority

201 Lung transplantation is the only intervention shown to i

202 Lung transplantation is the only therapeutic option in e

203 Lung transplantation is the only viable option for patie

204 (HA) fragments, in clinical or experimental lung transplantation is uncertain.

205 h is one of the most common infections after lung transplantation, is associated with chronic lung al

206 syndrome (BOS), the major cause of death on lung transplantation, is characterized by bronchiolar in

207 d as per International Society for Heart and Lung Transplantation (ISHLT) criteria.

208 eased by International Society for Heart and Lung Transplantation (ISHLT) established diagnostic crit

209 fined as International Society for Heart and Lung Transplantation (ISHLT) grade 2R or higher at endom

210 The International Society of Heart and Lung Transplantation (ISHLT) has initiated a multidiscip

211 The International Society for Heart and Lung Transplantation (ISHLT) registry was used to identi

212 using the International Society for Heart & Lung Transplantation (ISHLT)-defined criteria.

213 immunosuppression, long-term survival after lung transplantation lags behind that for other solid or

214 Performing lobar lung transplantation (LLT) can circumvent issues with do

215 one, or were on the waiting list to undergo, lung transplantation, lobectomy, or lung volume-reductio

216 In lung transplantation, long-term management remains limit

217 act the time to development of BOS or RAS in lung transplantation (low vs high LVD: 38.5 vs 86.0 mont

218 on (ACR) is a major early complication after lung transplantation (LT) and is a risk factor for chron

219 hepatitis B (HBV) vaccination strategies for lung transplantation (LT) candidates are not well establ

220 fects of geographic disparities on access to lung transplantation (LT) in the United States.

221 Lung transplantation (LT) is an established treatment fo

222 imus twice-daily (TAC BID) is widely used in lung transplantation (LT), but there are little data on

223 After lung transplantation (LT), early prediction of grade 3 p

224 After lung transplantation (LT), immunoglobulin (Ig) G plasma

225 essive lung destruction ultimately requiring lung transplantation (LT).

226 Sarcoidosis is reported to recur after lung transplantation (LT).

227 stone of monitoring allograft function after lung transplantation (LT).

228 disorders (SRBD) are common in patients with lung transplantation (LT); however, there are few data a

229 case series to date of hyperammonemia after lung transplantation (LTx) and discuss a treatment proto

230 Successful lung transplantation (LTx) depends on multiple component

231 Lung transplantation (LTx) has been reported in small nu

232 Lung transplantation (LTx) is offered to older and more

233 significant regional variations in COVID-19, lung transplantation (LTx) remains a critical life-savin

234 etting, although long-term outcome after DCD lung transplantation (LTx) remains largely unknown.

235 ronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx) results from bronchial epithe

236 nt cause of early morbidity and mortality in lung transplantation (LTX) with an incidence of 8% to 20

237 describe the frequency of tobacco use after lung transplantation (LTx), pretransplant patient charac

238 rome (BOS) remain major limiting factors for lung transplantation (LTx).

239 t of patients with various diseases awaiting lung transplantation (LTx).

240 olitis (LB), and respiratory infection after lung transplantation (LTx).

241 ease the number of donor lungs available for lung transplantation (LTx).

242 irect the length of antiviral prophylaxis in lung transplantation (LTx).

243 corporeal life support (ECLS) as a bridge to lung transplantation (LuTx) is a promising option for pa

244 dicate that lymphatic vessel formation after lung transplantation mediates HA drainage and suggest th

245 ung procurement and recipient survival after lung transplantation.Methods: We included all reported d

246 using either porcine venous tissue or a pig lung transplantation model, which recapitulates pulmonar

247 subjects with nondiseased lungs donated for lung transplantation (n = 11) and those with chronic obs

248 pulmonary disease (COPD) who were undergoing lung transplantation (n = 16) was evaluated for CCR2 wit

249 = 12), PWCF (n = 16), and PWCF after double-lung transplantation (n = 6).

250 Prognosis remains very poor, and currently lung transplantation offers the only hope of survival.

251 estigated the outcome of patients bridged to lung transplantation on ECLS technologies, mainly extrac

252 Heart-lung transplantation or bilateral lung transplantation i

253 ted hospitalization, death, or lung surgery (lung transplantation or pulmonary endarterectomy) during

254 ression of disease to warrant evaluation for lung transplantation (or retransplantation).

255 erwent single-lung and 2124 underwent double-lung transplantation) or COPD (n = 3174, of whom 1299 un

256 osuppression and composite endpoints (death, lung transplantation, or FVC decline) for those with an

257 ill associated with higher rates of death or lung transplantation (P<0.01).

258 We performed a single-center cohort study of lung transplantation patients with surgical biopsies of

259 as also present in bronchoalveolar lavage of lung transplantation patients.

260 evious results TTV-DNA levels increase after lung transplantation reaching a steady state after 3 mon

261 CMV-seropositive lung transplantation recipients were included in the dis

262 Lobar lung transplantation recipients were older (54 +/- 10 vs

263 nce from International Society for Heart and Lung Transplantation recommends using body weight for do

264 sing the International Society for Heart and Lung Transplantation Registry, we performed descriptive

265 jectors; International Society for Heart and Lung Transplantation rejection grade >/= 2R) and patient

266 The International Society for Heart and Lung Transplantation released a consensus statement in 2

267 Given that long-term outcomes following lung transplantation remain profoundly limited by chroni

268 Long-term survival after lung transplantation remains poor, yet modifiable risk f

269 Long-term survival after lung transplantation remains profoundly limited by graft

270 ntation) were identified as having undergone lung transplantation since May 2005.

271 After lung transplantation, spirometric values are routinely f

272 vious studies in a mouse model of orthotopic lung transplantation suggested a requirement for IL-17.

273 e progression are limited and often end with lung transplantation temporarily delaying an inevitable

274 The number of available donor organs limits lung transplantation, the only lifesaving therapy for th

275 key role in constrictive bronchiolitis after lung transplantation, the typical hallmark of chronic re

276 ts with worsening pulmonary disease awaiting lung transplantation, those supported via ECMO with spon

277 Subjects who underwent lung transplantation underwent endobronchial tissue oxim

278 review our experience using LLT and standard lung transplantation using a pediatric donor (PDLT) for

279 pact of using older donors on outcomes after lung transplantation using current protocols.

280 The unadjusted rate of lung transplantation was 94.5 per 100 person-years among

281 Time to death/lung transplantation was analyzed using Cox proportional

282 al need-based lung allocation system, double-lung transplantation was associated with better graft su

283 ssociated with poorer OS (P < 0.05), whereas lung transplantation was associated with no difference i

284 Unilateral left lung transplantation was performed in mice across varyin

285 m a prospective study of mental health after lung transplantation, we identified 1-year survivors and

286 T cells on bronchiolitis obliterans (BO) in lung transplantation, we used an established tracheal tr

287 nor specific anti-HLA antibodies (DSA) after lung transplantation were preemptively treated with ther

288 pulmonary veno-occlusive disease undergoing lung transplantation were significantly lower than those

289 f donors with at least one lung proposed for lung transplantation were ventilated with a protective s

290 nuary 2002 and January 2005, 209 consecutive lung transplantations were performed with LPD.

291 erwent single-lung and 1875 underwent double-lung transplantation) were identified as having undergon

292 n edema is a common early complication after lung transplantation where the hypoxia-induced vascular

293 ons with very severe COPD (n = 4) treated by lung transplantation with unused donor lungs (n = 4) ser

294 survival is acceptable in kidney, liver, and lung transplantation, with a proper selection and manage

295 he main reason for poor long-term outcome of lung transplantation, with bronchiolitis obliterans (BO)

296 he anastomosis within the first 3 days after lung transplantation, with more numerous and complex lym

297 incidence of graft rejection after liver and lung transplantation, with significantly higher rates of

298 dnDSA are common after lung transplantation, with the majority being DQ DSA.

299 mmunosuppressive drugs in kidney, liver, and lung transplantation without subsequent evidence of reje

300 ary disease as the number one indication for lung transplantation worldwide.